Quanta Presents Class-Leading Monotherapy Data for QTX3034 in KRAS G12D-Mutant Advanced Endometrial Cancer at the EORTC-NCI-AACR Symposium
QTX3034 achieved a 55% objective response rate, including a complete response, in heavily pretreated patients with KRAS G12D-mutant endometrial cancer Responses were rapid and durable, with median time to response of 1.3 months and median duration of response of 9.7 months 80%…